Peptide And Oligonucleotide CDMO Market Segments, Growth and Trends by Forecast by 2031

Historic Data: 2021-2023   |   Base Year: 2024   |   Forecast Period: 2025-2031

Peptide And Oligonucleotide CDMO Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage : by Product (Peptides, Oligonucleotides); Service Type (Contract Development, Contract Manufacturing); End Use (Pharmaceutical Companies, Biopharmaceutical Companies); and Geography (North America, Europe, Asia Pacific, and South and Central America)

  • Report Date : Jan 2026
  • Report Code : TIPRE00040673
  • Category : Life Sciences
  • Status : Upcoming
  • Available Report Formats : pdf-format excel-format
  • No. of Pages : 150
Page Updated: Mar 2025

The Peptide And Oligonucleotide CDMO Market is expected to register a CAGR of 12.5% from 2025 to 2031, with a market size expanding from US$ XX million in 2024 to US$ XX Million by 2031.

The report is segmented By Product (Peptides, Oligonucleotides), Service Type (Contract Development, Contract Manufacturing) End Use (Pharmaceutical Companies, Biopharmaceutical Companies). The global analysis is further broken-down at regional level and major countries. The Report Offers the Value in USD for the above analysis and segments.

Purpose of the Report

The report Peptide And Oligonucleotide CDMO Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:

  • Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
  • Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
  • Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.

Peptide And Oligonucleotide CDMO Market Segmentation

Product

  • Peptides
  • Oligonucleotides

Service Type

  • Contract Development
  • Contract Manufacturing

End Use

  • Pharmaceutical Companies
  • Biopharmaceutical Companies
Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Peptide And Oligonucleotide CDMO Market: Strategic Insights

peptide-and-oligonucleotide-cdmo-market
  • Get Top Key Market Trends of this report.
    This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Peptide And Oligonucleotide CDMO Market Growth Drivers

  • Rising Demand for Biopharmaceuticals: The rising demand for biopharmaceuticals is a key driver for the peptide and oligonucleotide Contract Development and Manufacturing Organization (CDMO) market. As the pharmaceutical industry increasingly shifts towards biologics for treating chronic diseases and genetic disorders, the need for specialized manufacturing services grows. CDMOs provide essential expertise in the production of complex molecules, facilitating faster market entry for innovative therapies.
  • Advancements in Biotechnology: Advancements in biotechnology significantly contribute to the growth of the peptide and oligonucleotide CDMO market. Innovations in synthesis techniques, purification methods, and analytical technologies enhance production efficiency and product quality. These advancements not only lower production costs but also expand the range of applications for peptides and oligonucleotides, driving demand for CDMO services as companies seek to leverage cutting-edge technologies.
  • Increasing Investment in Research and Development: The increasing investment in research and development by pharmaceutical and biotech companies is fueling the peptide and oligonucleotide CDMO market. As organizations prioritize the discovery of novel therapeutics, the demand for specialized manufacturing partners rises. CDMOs play a crucial role in supporting R&D efforts, offering scalable production capabilities and expertise, thereby enabling firms to accelerate their product pipelines and bring innovative therapies to market.

Peptide And Oligonucleotide CDMO Market Future Trends

  • Growth of Personalized Medicine: The growth of personalized medicine is a significant trend in the peptide and oligonucleotide CDMO market. As healthcare shifts towards tailored therapies that cater to individual patient needs, the demand for customized peptides and oligonucleotides is increasing. This trend encourages CDMOs to enhance their capabilities in developing specific formulations, thereby supporting the advancement of targeted treatments that improve patient outcomes.
  • Rising Adoption of Outsourcing Strategies: There is a notable rise in the adoption of outsourcing strategies among pharmaceutical companies, which is shaping the peptide and oligonucleotide CDMO market. By outsourcing drug development and manufacturing activities, companies can focus on their core competencies while leveraging the specialized expertise of CDMOs. This trend not only reduces operational costs but also accelerates the time-to-market for new therapeutics, driving growth in the CDMO sector.
  • Technological Innovations in Manufacturing: Technological innovations in manufacturing processes are transforming the peptide and oligonucleotide CDMO market. Advances in synthesis techniques, purification methods, and quality control measures enhance production efficiency and product quality. These innovations enable CDMOs to meet the increasing demand for complex biologics while ensuring compliance with stringent regulatory standards, positioning them as vital partners in the biopharmaceutical supply chain.

Peptide And Oligonucleotide CDMO Market Opportunities

  • Expansion into Emerging Markets: The expansion into emerging markets presents a valuable opportunity for the peptide and oligonucleotide CDMO market. As developing countries increase their investment in healthcare and biopharmaceuticals, there is a growing demand for specialized manufacturing services. By establishing a presence in these regions, CDMOs can capitalize on new business opportunities while supporting local companies in bringing innovative therapies to their markets.
  • Collaboration with Biotechnology Startups: The collaboration with biotechnology startups offers significant opportunities for the peptide and oligonucleotide CDMO market. Many startups seek experienced partners to help navigate the complexities of drug development and manufacturing. By forming strategic alliances, CDMOs can provide essential support, access to advanced technologies, and scalability, fostering innovation and contributing to the success of emerging therapies in the biopharmaceutical landscape.
  • Development of Next-Generation Therapies: The development of next-generation therapies, such as RNA-based treatments and engineered peptides, creates exciting opportunities for the peptide and oligonucleotide CDMO market. As research advances in these areas, the demand for specialized manufacturing processes increases. CDMOs that invest in cutting-edge technologies and expertise can position themselves as leaders in producing these innovative therapeutics, catering to the evolving needs of the biopharmaceutical industry.

Peptide And Oligonucleotide CDMO Market Regional Insights

The regional trends and factors influencing the Peptide And Oligonucleotide CDMO Market throughout the forecast period have been thoroughly explained by the analysts at The Insight Partners. This section also discusses Peptide And Oligonucleotide CDMO Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Peptide And Oligonucleotide CDMO Market Report Scope

Report Attribute Details
Market size in 2024 US$ XX million
Market Size by 2031 US$ XX Million
Global CAGR (2025 - 2031) 12.5%
Historical Data 2021-2023
Forecast period 2025-2031
Segments Covered By Product
  • Peptides
  • Oligonucleotides
By Service Type
  • Contract Development
  • Contract Manufacturing
By End Use
  • Pharmaceutical Companies
  • Biopharmaceutical Companies
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • PolyPeptide Group
  • STA Pharmaceutical Co. Ltd.
  • Bachem
  • Creative Peptides
  • Aurigene Pharmaceutical Services Ltd.
  • Merck KGaA
  • EUROAPI
  • Curia Global, Inc
  • CordenPharm
  • Sylentis, S.A.

Peptide And Oligonucleotide CDMO Market Players Density: Understanding Its Impact on Business Dynamics

The Peptide And Oligonucleotide CDMO Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.


peptide-and-oligonucleotide-cdmo-market-cagr

  • Get the Peptide And Oligonucleotide CDMO Market top key players overview

Key Selling Points

  • Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Peptide And Oligonucleotide CDMO Market, providing a holistic landscape.
  • Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
  • Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
  • Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.

The research report on the Peptide And Oligonucleotide CDMO Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.


Frequently Asked Questions

1

Who are the prominent players in Peptide And Oligonucleotide CDMO Market?

PolyPeptide Group, STA Pharmaceutical Co. Ltd, Bachem, Creative Peptides, Aurigene Pharmaceutical Services Ltd, Merck KGaA are the major companies operating in the Peptide And Oligonucleotide CDMO Market
2

Which is the fastest growing region in Peptide And Oligonucleotide CDMO Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast year (2025 - 2031)
3

Which region accounts for highest revenue share Peptide And Oligonucleotide CDMO Market?

The North America region accounts for highest revenue share Peptide And Oligonucleotide CDMO Market?
4

What years does this Peptide And Oligonucleotide CDMO Market?

The final report will duly include market size and projection estimates for all the segments from 2021 to 2031, along with a revenue share and compound annual growth rate (%) for the regional
/
country-wise market wherein 2021-2023 are the historic years, 2024 is considered to be the base year, and the forecast will be provided till 2031, along with CAGR (%)
5

At what CAGR the Peptide And Oligonucleotide CDMO Market projected to grow?

The market is expected to grow at a CAGR of 12.5%
6

Major driver boosting the Peptide And Oligonucleotide CDMO Market growth?

Rising Demand for Biopharmaceuticals is the major factors boosting the Peptide And Oligonucleotide CDMO Market growth
Mrinal Kerhalkar
Manager,
Market Research & Consulting

Mrinal is a seasoned research analyst with over 8 years of experience in Life Sciences Market Intelligence and Consulting. With a strategic mindset and unwavering commitment to excellence, she has built deep expertise in pharmaceutical forecasting, market opportunity assessment, and developing industry benchmarks. Her work is anchored in delivering actionable insights that empower clients to make informed strategic decisions.

Mrinal’s core strength lies in translating complex quantitative datasets into meaningful business intelligence. Her analytical acumen is instrumental in shaping go-to-market (GTM) strategies and uncovering growth opportunities across the pharmaceutical and medical device sectors. As a trusted consultant, she consistently focuses on streamlining workflow processes and establishing best practices, thereby driving innovation and operational efficiency for her clients.

  • Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
  • PEST and SWOT Analysis
  • Market Size Value / Volume - Global, Regional, Country
  • Industry and Competitive Landscape
  • Excel Dataset

Testimonials

Reason to Buy

  • Informed Decision-Making
  • Understanding Market Dynamics
  • Competitive Analysis
  • Identifying Emerging Markets
  • Customer Insights
  • Market Forecasts
  • Risk Mitigation
  • Boosting Operational Efficiency
  • Strategic Planning
  • Investment Justification
  • Tracking Industry Innovations
  • Aligning with Regulatory Trends
Our Clients
Sales Assistance
US: +1-646-491-9876
UK: +44-20-8125-4005
Email: sales@theinsightpartners.com
Chat with us
DUNS Logo
87-673-9708
ISO Certified Logo
ISO 9001:2015
ISO Certified Logo